Novel Epothilone Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer
Public ClinicalTrials.gov record NCT00080301. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III Trial of Novel Epothilone BMS-247550 Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer Previously Treated With or Resistant to an Anthracycline and Who Are Taxane Resistant
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this clinical research study is to learn if BMS-247550 added to the approved therapy of capecitabine is better than capecitabine alone in shrinking or slowing the growth of the cancer in women with metastatic breast cancer who are resistant to taxane and received anthracycline chemotherapy. The safety of this treatment will also be studied.
Study identification
- NCT ID
- NCT00080301
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 752 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 2003 (Type not available)
- Primary completion
- Nov 2006 (Actual)
- Completion
- Mar 2008 (Actual)
- Last update posted
- Nov 2, 2020
2003 – 2008
United States locations
- U.S. sites
- 32
- U.S. states
- 24
- U.S. cities
- 32
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution | Little Rock | Arkansas | — | — |
| Local Institution | San Francisco | California | — | — |
| Local Institution | Vallejo | California | — | — |
| Local Institution | Denver | Colorado | — | — |
| Local Institution | Hartford | Connecticut | — | — |
| Local Institution | Washington D.C. | District of Columbia | — | — |
| Local Institution | Orlando | Florida | — | — |
| Local Institution | Baltimore | Maryland | — | — |
| Local Institution | Burlington | Massachusetts | — | — |
| Local Institution | Jackson | Mississippi | — | — |
| Local Institution | Columbia | Missouri | — | — |
| Local Institution | Kansas City | Missouri | — | — |
| Local Institution | St Louis | Missouri | — | — |
| Local Institution | Omaha | Nebraska | — | — |
| Local Institution | Livingston | New Jersey | — | — |
| Local Institution | New Brunswick | New Jersey | — | — |
| Local Institution | Albuquerque | New Mexico | — | — |
| Local Institution | New York | New York | — | — |
| Local Institution | Columbus | Ohio | — | — |
| Local Institution | Oklahoma City | Oklahoma | — | — |
| Local Institution | Tulsa | Oklahoma | — | — |
| Local Institution | Pittsburgh | Pennsylvania | — | — |
| Local Institution | Columbia | South Carolina | — | — |
| Local Institution | Greenville | South Carolina | — | — |
| Local Institution | Knoxville | Tennessee | — | — |
| Local Institution | Nashville | Tennessee | — | — |
| Local Institution | Austin | Texas | — | — |
| Local Institution | Houston | Texas | — | — |
| Local Institution | Ogden | Utah | — | — |
| Local Institution | Burlington | Vermont | — | — |
| Local Institution | Tacoma | Washington | — | — |
| Local Institution | Morgantown | West Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 95 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00080301, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 2, 2020 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00080301 live on ClinicalTrials.gov.